Melanoma imaging using 111In-, 86Y- and 68Ga-labeled CHX-A″-Re(Arg11)CCMSH

Nuclear Medicine and Biology

Volumn 36, Issue 4, 2009, Pages 345-354

  Wei, Lihui ^a   Zhang, Xiuli ^b,c   Gallazzi, Fabio ^b   Miao, Yubin ^b,c   Jin, Xiaofang ^b   Brechbiel, Martin W ^d   Xu, Heng ^d   Clifford, Thomas ^d   Welch, Michael J ^a   Lewis, Jason S ^a   Quinn, Thomas P ^b,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Missouri   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

MSH; CHX A ; Imaging; Melanoma; Peptide

Indexed keywords

[RHENIUM(CYSTEINE 3,4,10) DEXTRO PHENYLALANINE 7 ARGININE 11]ALPHA MELANOCYTE STIMULATING HORMONE 3-13; ALPHA INTERMEDIN DERIVATIVE; ARGININE; GALLIUM 68; INDIUM 111; MELANOCORTIN 1 RECEPTOR; N (2 AMINOETHYL) TRANS 1,2 DIAMINOCYCLOHEXANE N,N',N' PENTAACETIC ACID; UNCLASSIFIED DRUG; YTTRIUM 86;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG CLEARANCE; DRUG UPTAKE; FEMALE; ISOTOPE LABELING; MELANOMA; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR DIAGNOSIS;

ALPHA-MSH; ANIMALS; CHELATING AGENTS; CYCLIZATION; FEMALE; GALLIUM RADIOISOTOPES; INDIUM RADIOISOTOPES; MELANOMA; MICE; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, MELANOCORTIN, TYPE 1; STAINING AND LABELING; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YTTRIUM RADIOISOTOPES;

EID: 67349128040     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.01.007     Document Type: Article

References (40)

1. Giblin M.F., Wang N., Hoffman T.J., Jurisson S.S., and Quinn T.P. Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc of the Natl Acad Sci U S A 95 (1998) 12814-12818
2. 7]-alpha-MSH, an alpha-melanocyte stimulating hormone analogue. Nucl Med Biol 24 (1997) 171-178
3. 99mttechnetium-labeled cyclic α-melanocyte stimulating hormone peptide analogues. Cancer Res 60 (2000) 5649-5658
4. 111In-DOTA-rhenium cyclized α-MSH analog: a novel cyclic-peptide analog with improved tumor targeting properties. J Nucl Med 42 (2001) 1847-1855
5. Froidevaux S., Calame-Christe M., Tanner H., Sumanovski L., and Eberle A.N. A novel DOTA-α-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J Nucl Med 43 (2002) 1699-1706
6. Froidevaux S., Calame-Christe M., Schuhmacher J., Tanner H., Saffrich R., Henze M., et al. A gallium-labeled DOTA-alpha-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med 45 (2004) 116-123
7. 11), a cyclic peptide analogue of α-MSH. J Med Chem 48 (2005) 2985-2992
8. 64Cu-labled rhenium-cyclized α-MSH peptide analogs using a cross-bridged cyclam chelator. J Nucl Med 48 (2007) 64-72
9. Wei L., Miao Y., Gallazzi F., Quinn T.P., Welch M.J., Vavere A.L., et al. Ga-68 Labeled DOTA-rhenium cyclized α-MSH analog for imaging of malignant melanoma. Nucl Med Biol 34 (2007) 945-953
10. 64Cu-Labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem 18 (2007) 765-772
11. 18F-labeled α-melanocyte stimulating hormone analog. J Nucl Med 48 (2007) 987-994
12. 188Re labeled α-melanocyte stimulating hormone peptide analogue in murine and human melanoma-bearing mouse models. J Nucl Med 46 (2005) 121-129
13. Miao Y., Hylarides M., Fisher D.R., Shelton T., Moore H., et al. Melanoma therapy via peptide-targeted alpha-radiation. Clin Cancer Res 11 (2005) 5616-5621
14. 177Lu labeled DOTA conjugated α-melanocyte stimulating hormone peptide in a murine melanoma-bearing mouse model. Cancer Biother Radiopharm 22 (2007) 333-341
15. Bard D.R., Knight C.G., and Page-Thomas D.P. A chelating derivative of α-melanocyte stimulating hormone as a potential imaging agent for malignant melanoma. Br J Cancer 62 (1990) 919-922
16. Wraight E.P., Bard D.R., Maughan T.S., Knight C.G., and Page-Thomas D.P. The use of a chelating derivative of alpha melanocytes stimulating hormone for the clinical diagnosis of malignant melanoma. Br J Radiol 65 (1992) 112-118
17. Hruby V.J., Cai M., Grieco P., Han G., Kavarana M., and Trivedi D. Exploring the stereostructural requirements of peptide ligands for the melanocortin receptors. Ann N Y Acad Sci 994 (2003) 12-20
18. Schioth H.B., Haitina T., Ling M.K., Ringholm A., Fredriksson R., Cerda-Reverter J.M., et al. Evolutionary conservation of the structural, pharmacological and genomic characteristics of melanocortin receptor subtypes. Peptides 26 (2005) 1886-1900
19. Roberts D.W., Newton R.A., Beaumont K.A., Leonard J.H., and Strum R.A. Quantitative analysis of MC1R gene expression in human skin cell cultures. Pigment Cell Res 19 (2005) 76-89
20. Siegrist W., Solca F., Stutz S., Giuffre L., Carrel S., Girard J., et al. Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells. Cancer Res 49 (1989) 6352-6358
21. Tatro J.B., Atkins M., Mier J.W., Hardarson S., Wolfe H., Smith T., et al. Melanotropin receptors demonstrated in situ in human melanoma. J Clin Invest 85 (1990) 1825-1832
22. Miao Y., Whitener D., Feng W., Owen N.K., Chen J.Q., and Quinn T.P. Evaluation of the human melanoma targeting properties of radiolabeled α-melanocyte stimulating hormone peptide analogues. Bioconjug Chem 14 (2003) 1177-1184
23. Schubiger P.A., Alberto R., and Smith A. Vehicles, chelators and radionuclides: choosing the "building blocks" of an effective therapeutic radioimmunoconjugate. Bioconjug Chem 7 (1996) 165-179
24. 111In labeled DOTA conjugated rhenium cyclized α-MSH analogs. J Med Chem 45 (2002) 3048-3056
25. 111In-labeled α-melanocyte stimulation hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. J Nucl Med 48 (2007) 73-80
26. 177Lu labeled alpha-melanocyte stimulating hormone peptide analogues in a murine melanoma model. Nucl Med Biol 32 (2005) 485-493
27. Brechbiel M.W., Gansow O.A., Pippen C.G., Rogers R.D., and Planalp R.P. Preparation of the novel chelating agent N-(2-aminoethyl)-trans-1,2-diaminocyclohexane N,N′,N′′-pentaacetic acid (H5CyDTPA), a preorganized analogue of diethylenetriaminepentaacetic acid (H5DTPA), and the structures of BiIII(CyDTPA)2- and BiIII(H2DTPA) complexes. Inorg Chem 35 (1996) 6343-6348
28. Milenic D.E., Garmestani K., Brady E.D., Albert P.S., Ma D.S., Abdulla A., et al. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res 10 (2004) 7834-7841
29. Huneke R.B., Pippin C.G., Squire R.A., Brechbiel M.W., Gansow O.A., and Strand M. Effective α-particle-mediated radioimmunotherapy of murine leukemia. Cancer Res 52 (1992) 5818-5820
30. 90Y-CHX-A′′-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478. Clin Cancer Res 11 (2005) 7080-7086
31. 90Y using a bifunctional DTPA chelating agent. Cancer Biother Radiopharm 18 (2003) 355-363
32. 177Lu for radioimmunotherapeutic applications. Nucl Med Biol 29 (2002) 431-442
33. Clifford T., Boswell C.A., Biddlecombe G.B., Lewis J.S., and Brechbiel M.W. Validation of a novel CHX-A′′ derivative suitable for peptide conjugation: small animal PET/CT imaging using yttrium-86-CHX-A′′-Octreotide. J Med Chem 49 (2007) 4297-4304
34. 86Y using a small biomedical cyclotron. Nuc Med Biol 32 (2005) 891-897
35. 7] α-Melanocyte stimulating hormone: a highly potent α-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A 77 (1980) 5754-5758
36. Stimmel J.B., Stockstill M.E., and Kull F.C. Yttrium-90 chelation properties of tetraazatetraacetic acid macrocycles, diethylenetriaminepenataacetic acid analogues, and a novel terpyridine acyclic chelator. Bioconjug Chem 6 (1995) 219-225
37. Catania A., Gatti S., Colombo G., and Lipton J.M. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev 56 (2004) 1-29
38. 203Pb-Labeled α-melanocyte stimulating hormone peptide as an imaging probe for melanoma detection. J Nucl Med 49 (2008) 823-829
39. Bernard B.F., Krenning E.P., Breeman W.A.P., Rolleman E.J., Bakker W.H., Visser T.J., et al. d-Lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 38 (1997) 1929-1933
40. Eckelman W.C., Volkert W.A., and Bonardi M. True radiotracers: are we approaching the theoretical specific activity with Tc-99m and I-123?. Nucl Med Biol 35 (2008) 523-527